Text: Question 12 (5 points)
PROBLEM 7. A manufacturer of antihistamine drug Allegra states that it contains 180 mg of fexofenadine hydrochloride per capsule as an active ingredient. To check the correctness of this statement, FDA randomly selects 29 Allegra capsules and finds the average amount of fexofenadine hydrochloride in them to be 189 mg with a standard deviation of 20.31 mg. If it is known that the content of fexofenadine hydrochloride in all Allegra capsules manufactured is normally distributed, does FDA have enough evidence to reject the manufacturer's statement at the level of significance α of 0.05?
QUESTION 1: State the hypotheses to be tested
Ho: μ = 180
Ha: μ < 180
Question 13 (5 points)
PROBLEM 7/QUESTION 2: Compute the p-value. (Round your answer to 3 decimal places)
0.012
Question 14 (5 points)
PROBLEM 7/QUESTION 3: Make your decision: Is there enough evidence to reject Ho at α = 0.05?
Yes: p-value = 0.012, so there is enough evidence to reject Ho at α = 0.05.